Seguir
Antonio Calles
Antonio Calles
Médico Especialista en Oncología Médica en Hospital General Universitario Gregorio Marañón
Dirección de correo verificada de salud.madrid.org
Título
Citado por
Citado por
Año
Expression of PD-1 and its ligands, PD-L1 and PD-L2, in smokers and never smokers with KRAS-mutant lung cancer
A Calles, X Liao, LM Sholl, SJ Rodig, GJ Freeman, M Butaney, C Lydon, ...
Journal of thoracic oncology 10 (12), 1726-1735, 2015
2532015
Carlumab, an anti-CC chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label …
I Brana, A Calles, PM LoRusso, LK Yee, TA Puchalski, S Seetharam, ...
Targeted oncology 10, 111-123, 2015
1962015
A functional landscape of resistance to ALK inhibition in lung cancer
FH Wilson, CM Johannessen, F Piccioni, P Tamayo, JW Kim, ...
Cancer cell 27 (3), 397-408, 2015
1792015
Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment
E Garralda, K Paz, PP López-Casas, S Jones, A Katz, LM Kann, ...
Clinical Cancer Research 20 (9), 2476-2484, 2014
1782014
Colon cancer molecular subtypes identified by expression profiling and associatedto stroma, mucinous type and different clinical behavior
B Perez Villamil, A Romera Lopez, S Hernandez Prieto, G Lopez Campos, ...
BMC cancer 12, 1-13, 2012
1522012
Response heterogeneity of EGFR and HER2 exon 20 insertions to covalent EGFR and HER2 inhibitors
T Kosaka, J Tanizaki, RM Paranal, H Endoh, C Lydon, M Capelletti, ...
Cancer research 77 (10), 2712-2721, 2017
1342017
Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma
A Calles, LM Sholl, SJ Rodig, AK Pelton, JL Hornick, M Butaney, C Lydon, ...
Clinical Cancer Research 21 (12), 2851-2860, 2015
1092015
Myocardial T1 and T2 mapping by magnetic resonance in patients with immune checkpoint inhibitor–associated myocarditis
P Thavendiranathan, L Zhang, A Zafar, ZD Drobni, SS Mahmood, ...
Journal of the American College of Cardiology 77 (12), 1503-1516, 2021
1082021
The role of immunotherapy in small cell lung cancer
A Calles, G Aguado, C Sandoval, R Álvarez
Clinical and Translational Oncology 21, 961-976, 2019
1082019
Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study
GJ Hanna, NL Busaidy, NG Chau, LJ Wirth, JA Barletta, A Calles, ...
Clinical cancer research 24 (7), 1546-1553, 2018
1042018
Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft
MP Morelli, E Calvo, E Ordoñez, MJ Wick, BR Viqueira, PP Lopez-Casas, ...
Journal of Clinical Oncology 30 (4), e45, 2012
922012
Checkpoint blockade in lung cancer with driver mutation: choose the road wisely
A Calles, JW Riess, JR Brahmer
American Society of Clinical Oncology Educational Book 40, 372-384, 2020
772020
Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline-and taxane-refractory breast cancer
JA Garcia-Saenz, M Martin, A Calles, C Bueno, L Rodriguez, J Bobokova, ...
Journal of chemotherapy 20 (5), 632-639, 2008
772008
Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer
AB Custodio, JL González-Larriba, J Bobokova, A Calles, R Alvarez, ...
Journal of thoracic oncology 4 (7), 891-910, 2009
712009
Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer
E Calvo, VJ Chen, M Marshall, U Ohnmacht, SM Hynes, E Kumm, ...
Investigational new drugs 32, 955-968, 2014
652014
Intratumoral nanoplexed poly I: C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors
I Márquez-Rodas, F Longo, ME Rodriguez-Ruiz, A Calles, S Ponce, ...
Science Translational Medicine 12 (565), eabb0391, 2020
622020
Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines
A Calles, N Kwiatkowski, BK Cammarata, D Ercan, NS Gray, PA Jänne
Molecular oncology 9 (1), 260-269, 2015
562015
Safety and pharmacokinetics/pharmacodynamics of the first-in-class dual action HER3/EGFR antibody MEHD7945A in locally advanced or metastatic epithelial tumors
D Juric, R Dienstmann, A Cervantes, M Hidalgo, W Messersmith, ...
Clinical Cancer Research 21 (11), 2462-2470, 2015
552015
Oncology patient interest in the use of new technologies to manage their disease: cross-sectional survey
R Collado-Borrell, V Escudero-Vilaplana, A Calles, E Garcia-Martin, ...
Journal of medical Internet research 20 (10), e11006, 2018
472018
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
B Gyawali, EGE De Vries, U Dafni, T Amaral, J Barriuso, J Bogaerts, ...
ESMO open 6 (3), 100117, 2021
432021
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20